Wed, Sep 17, 2014, 1:34 PM EDT - U.S. Markets close in 2 hrs 26 mins

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mtdsus mtdsus Feb 5, 2013 11:47 AM Flag

    Kay,Can you find out C-rp median of Reduce-IT study enrolled group?

    Kay,
    More researchers in Japan are reanalyzing JELIS data and finding that inflammation was a key factor in JELIS good results.I have seen 2 articles in 2011 and 2012.One was sent to me by Dr.Barry Sears.
    What is the median C-RP of Reduce-IT study participants? Can you find out?

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Mtdsus
      Heard back re HsCRP " will only be analyzed at the very end of the trial and is not a specific endpoint in this case "
      I have a blood test coming up in about 2 weeks . If I get my LDL down close to 100 with max dose Crestor and max dose Zetia --- I'll re apply for the Reduce it Trial . It seems a hard trial to get into -very strict requirements --- so lets hope they meet their 40% enrollment by the end of Feb --which I believe was their aim .

      AK

    • Mtdsus

      Direct from the Reduce it Trial
      1) Aim is to " follow a group who are likely to have an event " ---thus we " choose the higher risk patients --these patients are the most likely to benefit in the short term "

      2) Entry Criteria " Men and women over 45 with either Coronary Artery Disease ( heart attacks , stents , CABG ( bypass ? ) ) and/or diabetes with high blood pressure or some other risk factors such as low HDL "

      3) TG's 135 -500 and
      LDL 70-100 is required ..... Not concerned about which statin you use to get your LDL below 100 or if you also used Zetia with a statin to get LDL below 100.

      Previous email said they place a high emphasis on the patient having diabetes ... ie if you have not had a heart attack but had diabetes and other risk factors you could still qualify.
      No word on Hs CRP yet

      Its a very different trial IMHO then Jelis who seemed to have fairly health folks with slightly elevated LDL cholesterol...... Reduce it wants patients at high risk of "eventing "
      AK

    • Too early to get that baseline data and I believe all of the research companies operate under NDA's but I will look around.

      Sentiment: Strong Buy

    • Mtdsus
      I know some one working on the trial in Nth Ca ---I'll email them for you ---any other questions you want me to ask ?
      AK

      • 1 Reply to akanz2
      • Although my interest is C-RP,pl. try to find out what you can -about other parameters-like
        LDL -C levels,HDL and previous heart ailments.
        We know TG has to be greater than 150mg./dl.--but what is the median TG of all so far.Since this is part of Anchor deal with FDA--Median has to be between 200-500mg--but is the Median 400 or 300 mg?
        Of course-what Statin is being used mostly and its dosage? If most are using Crestor,then that indicates C-rp to be high. Thought--indirect information may give us clues for C-rp levels.
        My point: Are they enrolling people who are at high risk of Heart Attack?
        JELIS did not plan around the risks when selecting patients--but we know that people with TG greater than 150 and HDL less than 40 mg./dl. saw 53% reduction.
        How is Reduce-It selecting their participants?

 
AMRN
1.36+0.010(+0.74%)1:34 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.